BioCardia (NASDAQ:BCDA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research report released on Thursday morning,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

BioCardia Trading Down 4.0 %

Shares of NASDAQ:BCDA traded down $0.08 during midday trading on Thursday, reaching $1.94. 46,558 shares of the company were exchanged, compared to its average volume of 297,191. The stock has a market cap of $4.12 million, a PE ratio of -0.48 and a beta of 1.28. The business’s fifty day moving average is $2.59 and its two-hundred day moving average is $3.36. BioCardia has a one year low of $1.91 and a one year high of $14.40.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.78). As a group, sell-side analysts expect that BioCardia will post -5.06 EPS for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.